Clinical / Scientific Presentation and Publication Highlights

Preliminary Results of a Phase 1 Dose Escalation Study of The First-In-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, In Patients With Advanced B-Cell Malignancies. Nirav.. Read More →

.. Read More →

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in.. Read More →

Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer – Data is.. Read More →

Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety.. Read More →

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International.. Read More →

World Anti-Body Drug Conjugate (ADC) 2019  Process Development and Scale Up for Site-Specific Bioconjugate Conjugation and Purification Please Click the Link, World ADC 2019 Poster to.. Read More →

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a.. Read More →

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

International Conference in Malignant Lymphoma (ICML) 2019 Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001,.. Read More →

SOUTH SAN FRANCISCO, Calif., June 18, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application.. Read More →

European Hematology Association Congress (EHA) 2019 Preliminary results of a Phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in.. Read More →

Preliminary Results Of A Phase 1 Dose Escalation Study Of The First-In-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, In Patients With Advanced B-Cell Malignancies. Abstract.. Read More →

SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology.. Read More →

American Association for Cancer Research (AACR) 2019 Abstract 3897: Stability and safety evaluation of STRO-002, a site-specific anti-folate receptor alpha antibody-drug conjugate for the potential.. Read More →

American Association for Cancer Research (AACR) 2019 A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-002, An Anti-Folate Alpha (FolRα) Antibody Drug.. Read More →

American Association for Cancer Research (AACR) 2019 A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-001, An Anti-CD74 Antibody Drug Conjugate, In.. Read More →

SOUTH SAN FRANCISCO, Calif., April 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the.. Read More →

Non-Confi Presentation 1-19.. Read More →

Objectives: Folate receptor alpha (FolRa) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, and is thus a promising target for cancer therapy.. Read More →

Preclinical Activity and Safety of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian Cancer STRO-002 Rivkin Poster 08092018.. Read More →

 A PHASE 1 OPEN-LABEL, SAFETY, PHARMACOKINETIC, AND PRELIMINARY EFFICACY STUDY OF STRO-001, AN ANTI-CD74 ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES, NCT03424603 2018.. Read More →

American Association for Cancer Research (AACR) 2018 Discovery and Activity of STRO-002, a Novel ADC Targeting Folate Receptor Alpha for Ovarian and Endometrial Cancer STRO-002 AACR.. Read More →

Generation and Activity of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer   Folate receptor alpha (FolRa) is a glycosylphosphatidylinositol linked cell-surface.. Read More →

Preclinical Activity and Safety of STRO-002, a novel ADC targeting Folate Receptor Alpha for Ovarian Cancer   Objectives: Folate receptor alpha (FolRa) is a cell-surface.. Read More →

.. Read More →

Pan Pacific Lymphoma, 2018 HIGH FREQUENCY OF CD74 EXPRESSION IN B-CELL NON-HODGKIN’S LYMPHOMA (NHL) AND TARGETING WITH STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC).. Read More →

Biotechnol Bioeng. 2011 Jul;108(7):1570-8. doi: 10.1002/bit.23103. Epub 2011 Mar 31. Microscale to manufacturing scale-up of cell-free cytokine production–a new approach for shortening protein production development.. Read More →

High Frequency of CD74 Expression in B-cell Non-Hodgkin’s Lymphoma (NHL) and Targeting with STRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent In Vitro.. Read More →

Characterization and pre-clinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies  2017 combined MM and NHL AACR FINAL.. Read More →

Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin’s Lymphoma Arturo Molina, MD, MS Sutro Biopharma ASH Annual Meeting 2016.. Read More →

Discovery and preclinical development of novel CD74-targeting antibody-drug conjugates (ADCs) with significant activity in multiple myeloma (MM) cell lines and xenograft models 2016 DEC ASH.. Read More →

Yiren Xu, John Lee, Cuong Tran, Tyler H Heibeck, Willie D Wang, Junhao Yang, Ryan L Stafford, Alexander R Steiner, Aaron K Sato, Trevor J Hallam,.. Read More →

Toni Kline, Alexander R. Steiner, Kalyani Penta, Aaron K. Sato, Trevor J. Hallam, Gang Yin,  Methods to Make Homogenous Antibody Drug Conjugates Pharmaceutical Research December 2014,.. Read More →

Ryan L. Stafford,* Erik S. Zimmerman, Trevor J. Hallam, and Aaron K. Sato, A General Sequence Processing and Analysis Program for Protein Engineering, dx.doi.org/10.1021/ci500362s | J... Read More →

SAN FRANCISCO, Oct. 15, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology, presented today.. Read More →

Hallam, Trevor, Producing Homogeneous ADCs with Combination Warheads Presented at the 4th World ADC Summit, San Francisco (PDF) Read More.. Read More →

Christopher J Murray, and Ramesh Baliga, Cell-free translation of peptides and proteins: from high throughput screening to clinical production,  Current Opinion in Chemical Biology 2013,.. Read More →

Hallam, Trevor, Rapid Design and Manufacture of Single Species, Site-Specific ADCs using Cell-Free Synthesis with nnAAs. Presented at the 3rd World ADC Summit, San Francisco.. Read More →

Gang Yin, Eudean D. Garces, Junhao Yang, Juan Zhang, Cuong Tran, Alexander R. Steiner, Christine Roos, Sunil Bajad, Susan Hudak, Kalyani Penta, James Zawada, Sonia.. Read More →

James F. Zawada, Preparation and Testing of E. coli S30 In Vitro Transcription Translation Extracts Ribosome Display and Related Technologies Methods in Molecular Biology Volume.. Read More →

James F. Zawada, Gang Yin, Alexander R. Steiner, Junhao Yang, Alpana Naresh, Sushmita M. Roy, Daniel S. Gold, Henry G. Heinsohn, Christopher J. Murray, Microscale.. Read More →

Garces, Eudean et. al., A robust, rapid and scalable cell free expression system for the production and engineering of Fab antibodies. Presented at the IBC.. Read More →

Heibeck, Tyler H., et. al., Translation Fidelity Rate Determination in a Cell-Free Protein Synthesis System using LC-MS. 58th American Society for Mass Spectrometry Conference on.. Read More →

Rozzelle, James E., et.al., Towards scalable cell-free synthesis of non-native amino acid containing proteins. Presented at American Chemical Society Spring Meeting, San Francisco, CA. Read.. Read More →